Slow delayed rectifying potassium current (IKs) - analysis of the in vitro inhibition data and predictive model development

Journal of Applied Toxicology

Volumn 33, Issue 8, 2013, Pages 723-739

  Polak, Sebastian ^a   Wiśniowska, Barbara ^a   Glinka, Anna ^a   Fijorek, Kamil ^b   Mendyk, Aleksander ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b CRACOW UNIVERSITY OF ECONOMICS   (Poland)

Author keywords

IKs; IC50; KCNQ1; Potassium channels; Slow rectifying potassium current

Indexed keywords

DELAYED RECTIFIER POTASSIUM CHANNEL;

ALGORITHM; ARTICLE; ARTIFICIAL NEURAL NETWORK; CARDIOTOXICITY; CHEMICAL INTERACTION; EXPERT SYSTEM; HEART ELECTROPHYSIOLOGY; IC 50; IN VITRO STUDY; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; CRICETINAE; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; KCNQ1 POTASSIUM CHANNEL; MODELS, BIOLOGICAL; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS;

EID: 84879506173     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2719     Document Type: Article

References (71)

1. Ks. Bioorg. Med. Chem. Lett. 14: 99-102; doi: 10.1016/j.bmcl.2003.10.003
2. Bachmann A, Mueller S, Kopp K, Brueggemann A, Suessbrich H, Gerlach U, Busch AE. 2002. Inhibition of cardiac potassium currents by pentobarbital. Naunyn-Schmiedeberg's Arch. Pharmacol. 365: 29-37; doi: 10.1007/s00210-001-0490-1
3. Bentzen BH, Schmitt N, Calloe K, Brown WD, Grunnet M, Olesen S-P. 2006. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology 51: 1068-1077; doi: 10.1016/j.neuropharm.2006.07.001
4. Bett GCL, Morales MJ, Beahm DL, Duffey ME, Rasmusson RL. 2006. Ancillary subunits and stimulation frequency determine the potency of chromanol 293B block of the KCNQ1 potassium channel. J. Physiol. 576(3): 755-767; doi: 10.1113/jphysiol.2006.116012
5. Bilski J. 2000. The backpropagation learning with logarithmic transfer function. Proceedings of the Fifth Conference Neural Networks and Soft Computing, Zakopane, Poland, 6-10 June; Conference Materials; 71-77.
6. Breiman L. 2001. Random forests. Mach. Learn. 45: 5-32; doi: 10.1023/A:1010933404324
7. Busch E, Eigenberger B, Jurkiewicz NK, Salata JJ, Pica A, Suessbrich H, Lang F. 1998. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action. Br. J. Pharmacol. 123: 23-30; doi: 10.1038/sj.bjp.0701575
8. Chadwick D, Goode J. 2005. The hERG Cardiac Potassium Channel: Structure, Function and Long QT Syndrome. John Wiley & Sons: Chichester.
9. Champeroux P, Ouille A, Martel E, Sinclair J, Fowler L, Maurin A, Richard S, Le Guennec J-Y. 2011. A step towards characterisation of electrophysiological profile of torsadogenic drugs. J. Pharmacol. Toxicol. Meth. 63(3): 269-278; doi: 10.1016/j.vascn.2011.01.001
10. Cheng J, Niwa R, Kamiya K, Toyama J, Kodama I. 1999. Carvedilol blocks the repolarizing Kq currents and the L-type Ca2q current in rabbit ventricular myocytes. Eur. J. Pharmacol. 376: 189-201; doi: 10.1016/S0014-2999(99)00368-4
11. Chouabe C, Drici M-D, Romey G, Barhanin J, Lazdunski M. 1998. HERG and KvLQT1/IsK, the cardiac K1 channels involved in long QT syndromes, are targets for calcium channel blockers. Mol. Pharmacol. 54: 695-703.
12. Drolet B, Vincent F, Rail J, Chahine M, Deschenes D, Nadeau S, Khalifa M, Hamelin BA, Turgeon J. 1999. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J. Pharmacol. Exp. Ther. 288: 1261-1268.
13. Drolet B, Yang T, Daleau P, Roden DM, Turgeon J. 2003. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J. Cardiovasc. Pharmacol. 41(6): 934-937; doi: 10.1097/00005344-200306000-00016
14. Ks. Br. J. Pharmacol. 159: 93-101; doi: 10.1111/j.1476-5381.2009.00371.x
15. Ks' channels incorporating the V307L KCNQ1 mutation. J. Physiol. Pharmacol. 61(2): 123-131.
16. Fossa AA, Wisialowski T, Wolfgang E, Wang E, Avery M, Raunig DL, Fermini B. 2004. Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. Eur. J. Pharmacol. 486(2): 209-221; doi: 10.1016/j.ejphar.2003.12.028
17. Gautier P, Guillemare E, Djandjighian L, Marion A, Planchenault J, Bernhart C, Herbert J-M, Nisato D. 2004. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C. Electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J. Cardiovasc. Pharmacol. 44(2): 244-257; doi: 10.1097/00005344-200408000-00015
18. Ks channels by HMR 1556. Naunyn-Schmiedeberg's Arch. Pharmacol. 362: 480-488; doi: 10.1007/s002100000284
19. Gómez R, Núñez L, Caballero R, Vaquero M, Tamargo J, Delpón E. 2005. Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1ţminK channels. Br. J. Pharmacol. 146: 146-161; doi: 10.1038/sj.bjp.0706302
20. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. 2009. The WEKA data mining software: an update. SIGKDD Explorations 11(1): 10-18; doi: 10.1145/1656274.1656278
21. Ks current (hKCNQ1/hKCNE1) stably expressed in HEK-293 cells. Am. J. Physiol. Heart Circul. Physiol. 295: H1867-H1881; doi: 10.1152/ajpheart.433.2008
22. + currents in guinea-pig ventricular myocytes. Br. J. Pharmacol. 131: 1809-1816; doi: 10.1038/sj.bjp.0703758
23. Jones SE, Yuji K, Shuba LM, Ogura T, McCullough JR, McDonald TF. 2000b. Analysis of the electrophysiologic effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. J. Cardiovasc. Pharmacol. 35(2): 334-340; doi: 10.1097/00005344-200002000-00024
24. Kane JM, Potkin SG, Daniel DG, Buckley PF. 2011. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J. Clin. Psychiat. 72(2): 194-204; doi: 10.4088/JCP.07m03733yel
25. Kang J, Chen X-L, Wang L, Rampe D. 2001. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J. Pharmacol. Exp. Ther. 299: 290-296.
26. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. 2006. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J. Pharmacol. Exp. Ther. 316(3): 1098-1106; doi: 10.1124/jpet.105.093393
27. Khalifa M, Drolet B, Daleau P, Lefez C, Gilbert M, Plante S, O'Hara GE, Gleeton O, Hamelin BA, Turgeon J. 1999. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J. Pharmacol. Exp. Ther. 288: 858-865.
28. Ko CM, Ducic I, Fan J, Shuba JM, Morad M. 1997. Suppression of mammalian K1 channel family by ebastine. J. Pharmacol. Exp. Ther. 281: 233-244.
29. Kongsamut S, Kang J, Chen X-L, Roehr J, Rampe D. 2002. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 450(1): 37-41; doi: 10.1016/S0014-2999(02)02074-5
30. Lacerda AE, Kramer J, Shen KZ, Thomas D, Brown AM. 2001. Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur. Heart J. Suppl. 3 (suppl. K): K23-K30; doi: 10.1016/S1520-765X(01)90003-3
31. Lacerda AE, Kuryshev YA, Yan G-X, Waldo AL, Brown AM. 2010. Vanoxerine: cellular mechanism of a new antiarrhythmic. J. Cardiovasc. Electrophysiol. 21: 301-310; doi: 10.1111/j.1540-8167.2009.01623.x
32. Lerche C, Bruhova I, Lerche H, Steinmeyer K, Wei AD, Strutz-Seebohm N, Lang F, Busch AE, Zhorov BS, Seebohm G. 2007. Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter. Mol. Pharmacol. 71: 1503-1511; doi: 10.1124/mol.106.031682
33. Liu H, Yang L, Jin M-W, Sun H-Y, Huang Y, Li G-R. 2010. The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation. Pharmacol. Res. 62: 384-390; doi: 10.1016/j.phrs.2010.07.008
34. Ks blockers. J. Med. Chem. 44: 3764-3767; doi: 10.1021/jm015505u
35. Loussouarn G, Charpentier F, Mohammad-Panah R, Kunzelmann K, Baró I, Escande D.1997. KvLQT1 Potassium channel but not IsK is the molecular target for trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2, 2-dimethyl-chromane. Mol. Pharmacol. 52: 1131-1136.
36. Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R, Pugsley M, Gallacher DJ. 2008. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br. J. Pharmacol. 154(7): 1427-1438; doi: 10.1038/bjp.2008.191
37. Magyar J, Szentandrássy N, Bányász T, Fülöp L, Varró A, Nánási PP. 2002. Effects of thymol on calcium and potassium currents in canine and human ventricular cardiomyocytes. Br. J. Pharmacol. 136: 330-338; doi: 10.1038/sj.bjp.0704718
38. Mendyk A, Jachowicz R. 2005. Neural network as a decision support system in the development of pharmaceutical formulation - focus on solid dispersions. Expert Syst. Applic. 28(2): 285-294; doi: 10.1016/j.eswa.2004.10.007
39. Mendyk A, Kleinebudde P, Thommes M, Yoo A, Szlek J, Jachowicz R. 2010. Analysis of pellet properties with use of artificial neural networks. Eur. J. Pharm. Sci. 41(3-4): 421-429; doi: 10.1016/j.ejps.2010.07.010
40. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D. 2011. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc. Res. 91(1): 53-61; doi: 10.1093/cvr/cvr044
41. + currents by nisoldipine. Br. J. Pharmacol. 140(5): 863-870; doi: 10.1038/sj.bjp.0705518
42. Möller C, Netzer R. 2006. Effects of estradiol on cardiac ion channel currents. Eur. J. Pharmacol. 532(1-2): 44-49; doi: 10.1016/j.ejphar.2006.01.006
43. Moreno I, Caballero R, González T, Arias C, Valenzuela C, Iriepa I, Gálvez E, Tamargo J, Delpón E. 2003. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J. Pharmacol. Exp. Ther. 304: 862-873; doi: 10.1124/jpet.102.042325
44. Obiol-Pardo C, Sanz F, Pastor M, Gomis-Tena J, Saiz J. 2011. A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J. Chem. Inf. Model. 51(2): 483-492; doi: 10.1021/ci100423z
45. Persson F, Carlsson L, Duker G, Jacobson I. 2005. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J. Cardiovasc. Electrophysiol. 16: 329-341; doi: 10.1046/j.1540-8167.2005.40427.x
46. Polak S, Wisniowska B, Ahamadi M, Mendyk A. 2011a. Prediction of the hERG potassium channel inhibition potential with use of artificial neural networks. Appl. Soft. Comp. 11(2): 2611-2617; doi: 10.1016/j.asoc.2010.09.010
47. Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. 2011b. The open-access dataset for in silico cardiotoxicity prediction system. Bioinformation. 6(6): 244-245.
48. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. 2003. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58(1): 32-45; doi: 10.1016/S0008-6363(02)00846-5
49. Ks currents in rat sino-atrial nodal cells. Eur. J. Pharmacol. 407: 123-129; doi: 10.1016/S0014-2999(00)00734-2
50. Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. 2004. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br. J. Pharmacol. 142: 1300-1308; doi: 10.1038/sj.bjp.0705879
51. Seebohm G, Chen J, Strutz N, Culberson C, Lerche C, Sanguinetti MC. 2003. Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol. Pharmacol. 64: 70-77; doi: 10.1124/mol.64.1.70
52. Shevade SK, Keerthi SS, Bhattacharyya C, Murthy KRK. 1999. Improvements to SMO algorithm for SVM regression. Technical Report CD-99-16, Control Division Department of Mechanical and Production Engineering, National University of Singapore.
53. Shimizu A, Ryoko N, Lu Z, Haruo H, Kamiya K. 2003. Effects of dronedarone on HERG and KCNQ1/KCNE1 Channels. Environ. Med. 47: 48-50.
54. Smola AJ, Scholkopf B. 1998. A tutorial on support vector regression. NeuroCOLT2 Technical Report Series - NC2-TR-1998-030.
55. Sperelakis N. 2011. Cell Physiology Source Book: Essentials of Membrane Biophysics. Academic Press: London.
56. Suessbrich H, Waldegger S, Lang F, Busch AE. 1996. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 385(1-2): 77-80; doi: 10.1016/0014-5793(96)00355-9
57. Suessbrich H, Schönherr R, Heinemann SH, Attali B, Lang F, Busch AE. 1997. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br. J. Pharmacol. 120: 968-974; doi: 10.1038/sj.bjp.0700989
58. Takács J, Iost N, Lengyel C, Virág L, Nesic M, Varró A, Papp JG. 2003. Multiple cellular electrophysiological effects of azimilide in canine cardiac preparations. Eur. J. Pharmacol. 470: 163-170; doi: 10.1016/S0014-2999(03)01792-8
59. Thomsen MB, Volders PGA, Stengl M, Spätjens RLHMG, Beekman JDM, Bischoff U, Kall MA, Frederiksen K, Matz J, Vos MA. 2003. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J. Pharmacol. Exp. Ther. 307(2): 776-784; doi: 10.1124/jpet.103.052753
60. Tian M, Dong M-Q, Chiu S-W, Lau C-P, Li G-R. 2006. Effects of the antifungal antibiotic clotrimazole on human cardiac repolarization potassium currents. Br. J. Pharmacol. 147: 289-297; doi: 10.1038/sj.bjp.0706590
61. Ks potassium channel: an overlooked cardiovascular liability in drug safety screening? J. Pharmacol. Toxicol. Meth. 60(1): 1-10; doi: 10.1016/j.vascn.2009.04.197
62. Trepakova ES, Dech SJ, Salata JJ. 2006. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current. J. Cardiovasc. Pharmacol. 47(2): 211-220; doi: 10.1097/01.fjc.0000200810.18575.80
63. + current, by the diuretic agent indapamide in guinea pig myocytes. Circul. Res. 75: 879-886; doi: 10.1161/01.RES.75.5.879
64. Ks, in guinea-pig ventricular myocytes. Br. J. Pharmacol. 128: 1733-1738; doi: 10.1038/sj.bjp.0702959
65. Witchel HJ. 2011. Drug-induced hERG block and long QT syndrome. Cardiovasc. Ther. 29(4): 251-259; doi: 10.1111/j.1755-5922.2010.00154.x
66. Yager RR, Filev DP. 1994. Essentials of Fuzzy Modeling and Control. John Wiley & Sons: New York.
67. + current in guinea pig ventricular myocytes. Cardiovasc. Drugs Ther. 16: 317-325; doi: 10.1023/A:1021781926294
68. Ks potassium current by amiodarone in guinea pig ventricular myocytes. J. Cardiovasc. Electrophysiol. 16: 314-322; doi: 10.1046/j.1540-8167.2005.40561.x
69. + currents by nifedipine. Eur. J. Pharmacol. 401: 137-143; doi: 10.1016/S0014-2999(00)00413-1
70. Zurada JM. 1992. Introduction to Artificial Neural Systems. West: USA.
71. Zurada JM, Malinowski A, Usui S. 1997. Perturbation method for deleting redundant inputs of perceptron networks. Neurocomputing. 14: 177-193; doi: 10.1016/S0925-2312(96)00031-8